CAS: 77-37-2; Procyclidine

上下游产品

1-phenyl-3-(pyrrolidin-1-yl)propan-1-one cyclohexylmagnesium bromide Pyrrinol ethyl 3-tetrahydro-1H-1-pyrrolilpropanoate(+/-)-1-ethyl-1-(3-cyclohexyl-3-hydroxy-3-phenyl-propyl)-pyrrolidinium; iodide (+/-)-1-(3-cyclohexyl-3-hydroxy-3-phenyl-propyl)-1-methyl-pyrrolidinium; iodide (S)-Pr°Cyclidine (R)-Pr°Cyclidine

📜Alpha,Alpha-二苯基吡咯烷-1-丙醇置于溶剂黄146,铂体系中,化学反应生成 环苯咯丙醇
参考文献:Adamson Et Al.,Journal Of The Chemical Society,1951,P. 52,58
标题:Adamson Et Al.,Journal Of The Chemical Society,1951,P. 52,58

专利信息

专利号:WO-2025128098-A1
优先权日:2023-12-13
标 题 :Solid oral dosage forms, kits, and methods of using the same
发明人：LI YING; LANGER ROBERT; TRAVERSO CARLO
权利人:MASSACHUSETTS INST TECHNOLOGY; BRIGHAM & WOMENS HOSPITAL INC
摘要:Provided herein are solid oral dosage forms, methods, and kits useful, e.g, for the extension of the residence time of active pharmaceutical agents in vivo by the synthesis of a polymer in situ in a subject. In particular, the solid oral dosage forms, methods, and kits disclosed herein are particularly useful for drugs that require more than once daily administration (e.g, drugs that have short half-lives).

专利号:US-2009285888-A1
优先权日:2005-05-13
标题:Derivatives of dihydroxyphenylalanine
发明人：SUSILO GISELA
权利人:SUSILO GISELA
摘要:The invention relates to derivatives of dihydroxyphenylalanine, to their synthesis and to pharmaceutical compositions containing said derivatives of dihydroxyphenylalanine. Furthermore, the invention relates to the use of said derivatives of dihydroxyphenylalanine and said pharmaceutical compositions for the treatment and prophylaxis of movement disorders, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, hemiparkinson-hemiatrophy, parkinsonian syndrome, Lewy body disease, frontotemporal dementia, Lytico-Bodig disease (parkinsonism/dementia/amyotrophic lateral sclerosis), striatonigral degeneration, Shy-Drager syndrome, sporadic olivopontocerebellar degeneration, progressive atrophy of the globus pallidus, progressive supranuclear palsy, Hallervorden-Spatz disease, Huntington's disease, X-linked dystonia-parkinsonism (Lubag), mitochondrial cytopathy with striatal necrosis, neuroacanthocytosis, restless legs syndrome, Wilson's disease.

专利号:US-8318938-B2
优先权日:2006-02-21
标 题:Trans-fused chromenoisoquinolines synthesis and methods for use
发明人：NICHOLS DAVID; WATTS VAL J
权利人:NICHOLS DAVID; WATTS VAL J; PURDUE RESEARCH FOUNDATION
摘要:Optionally substituted chromenoisoquinolines and analogs and derivatives thereof are described herein. In addition, syntheses of these compounds are described herein. In addition, uses of these compounds as dopamine receptor binding compounds are described herein.

专利号:US-10458995-B2
优先权日:2016-03-25
标 题 :Combinatorial synthesis and biomarker development
发明人：MOOLA MURALIDHAR REDDY
权利人:MOOLA MURALIDHAR REDDY
摘要:Provided herein are methods, kits, and compositions for use in the diagnosis and treatment of diseases. Peptoids recognized by Alzheimers disease specific antibodies are identified.

专利号:US-2023271983-A1
优先权日:2020-07-29
标题 :Functionalized isonitriles and products, preparation and uses thereof
发明人：SOTELO PÉREZ EDDY; AZUAJE GUERRERO JHONNY ALBERTO; MAJELLARO MARIA
权利人:UNIV SANTIAGO COMPOSTELA
摘要:The present invention relates to functionalized isonitrile compounds, formed by means of multicomponent environmentally friendly reactions, suitable for coupling to functional molecules such as biomolecules, APIs, chromophore and fluorophore molecules. The invention also relates to conjugates between said isonitrile compounds and functional molecules, which are useful in the synthesis of pharmaceutic drugs or tools, fluorescent molecules and labels, polymeric smart materials. The invention furthermore provides a kit for the in-vitro preparation of the functionalized isontrile compounds and conjugates. The invention also contemplates the medical use of said compounds and conjugates.

专利号:US-9617230-B2
优先权日:2014-12-22
标题:Creatine prodrugs, compositions and methods of use thereof
发明人：BRUBAKER WILLIAM F
权利人:FARMINGTON PHARMA DEV
摘要:The invention describes membrane permeable creatine prodrugs, pharmaceutical compositions comprising membrane permeable creatine prodrugs, and methods of treating diseases such as ischemia, heart failure, neurodegenerative disorders and genetic disorders affecting the creatine kinase system comprising administering creatine prodrugs or pharmaceutical compositions thereof. The invention also describes treating a genetic disease affecting the creatine kinase system, such as, for example, a creatine transporter disorder or a creatine synthesis disorder comprising administering creatine prodrugs or pharmaceutical compositions thereof.